Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORZA pharmacokinetic interaction study of fosamprenavir/ritonavir and olanzapine
NL-OMON33257Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of fosamprenavir, ritonavir and olanzapine in Schizophrenia Spectrum Disorders (SSD) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Influence of fosamprenavir/ritonavir on single-dose pharmacokinetics of olanzapine. Started Dec 2009; status: active, not recruiting.
02
Drugs
fosamprenavirritonavirolanzapine
03
Conditions
Schizophrenia Spectrum Disorders (SSD)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON33257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33257.